In the randomised, three-arm, non-comparative phase II SECOMBIT trial, patients with previously untreated, metastatic BRAF V600-mutated melanoma were randomly assigned to arm A (n = 69; encorafenib–binimetinib until disease progression and then ipilimumab–nivolumab), arm B (n = 71; ipilimumab–nivolumab until disease progression and then encorafenib–binimetinib) or arm C (n = 69; encorafenib–binimetinib for 8 weeks followed by ipilimumab–nivolumab until disease progression and then encorafenib–binimetinib). The gene discussed is BRAF; the disease is melanoma.